Esophageal cancer remains one of the world's deadliest cancers, ranking 7th in incidence and 6th in cancer-related deaths ...

Merck’s investigational KRAS G12C inhibitor, MK-1084 shows antitumor activity in phase 1 trial of patients with advanced CRC and NSCLC whose tumours harbour KRAS G12C mutations Rahway, New Jersey ...

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 ...

Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted ...

Anal cancer is relatively uncommon, accounting for approximately 2.5% of all gastrointestinal cancers. Nonetheless, its ...

5-fluorouracil is a thymine analog. Via an unknown mechanism it acts selectively on AK dysplastic cells, causing apoptosis and destruction. Another advantage of this medication is that it allows ...

On May 9, 2025, the Tianjin Municipal Administration for Market Regulation (“Tianjin AMR”) announced administrative penalties ...

The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the launch of a groundbreaking grant program in partnership with Gilead Sciences aimed at advancing the field of ...

In talks at the annual meeting of the American Society of Clinical Oncology (ASCO), experts from Roswell Park Comprehensive Cancer Center will give remarks on racial and ethnic disparities in outcomes ...

Several companies are advancing treatments for anal cancer, including Merck (KEYTRUDA), BioMimetix (BMX-001), Novartis (KFA115), and Bicara Therapeutics (BCA101), among others. As immunotherapy ...